CANbridge Pharmaceuticals Inc.

As of December 31, 2024, CANbridge Pharmaceuticals Inc. carries a market capitalization of 56.50M, placing it among publicly traded companies globally. Its enterprise value stands at 190.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CANbridge Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2024, CANbridge Pharmaceuticals Inc. has 424.84M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, CANbridge Pharmaceuticals Inc. maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, CANbridge Pharmaceuticals Inc.'s stock has declined approximately 17.78% over the past 52 weeks. The 50-day moving average sits at 1.96, while the 200-day moving average is 2.25.

As of December 31, 2024, CANbridge Pharmaceuticals Inc. holds 10.68M in cash and equivalents against 144.50M in total debt, resulting in a net debt position of 21.64M. Total book value stands at -504.96M, with working capital of -465.34M providing operational flexibility.